STAT3 and non-small cell lung carcinoma: It is evident from the above findings that STAT3 plays an important role in immunosuppression by regulating the expression of the immune checkpoint protein PD-L1 in both cancer and immune cells and may be a promising therapeutic target that can be modulated in order to overcome resistance to and enhance the efficacy of immune checkpoint inhibitors in NSCLC.